Novavax Initiates Phase 1/2 Clinical Trial of Combination Vaccine for COVID-19 and Seasonal Influenza
GAITHERSBURG, Md., Sept. 8, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced enrollment of the first... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - September 8, 2021 Category: Pharmaceuticals Source Type: clinical trials

Unvaccinated Are Nearly 6x More Likely to End Up in the Hospital, According to Analysis of New Jersey's COVID Cases
PRINCETON, N.J., Sept. 7, 2021 - Those who are unvaccinated were nearly six times more likely to be hospitalized with severe COVID illness in August than those who have received the vaccine, according to a New Jersey Hospital Association analysis of... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - September 7, 2021 Category: Pharmaceuticals Source Type: clinical trials

Travere Therapeutics Announces Successful Outcome from Type A Meeting with U.S. FDA for Sparsentan in Focal Segmental Glomerulosclerosis
SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced a successful outcome from the Company’s Type A meeting with the U.S. Food and Drug Administration (FDA) in... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - September 7, 2021 Category: Pharmaceuticals Source Type: clinical trials

Valbiotis Announces the Completion of Recruitment for the Phase II HEART Clinical Study Conducted With TOTUM •070 in Hypercholesterolemia
LA ROCHELLE, France. Sept 6, 2021 - Valbiotis, a French research and development company committed to scientific innovation for preventing and combating metabolic diseases, announces that it has completed the recruitment of 120 volunteers for the... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - September 6, 2021 Category: Pharmaceuticals Source Type: clinical trials

New Tezepelumab Data Show 86% Reduction In Exacerbations In Patients With Severe Asthma And Comorbid Nasal Polyps
THOUSAND OAKS, Calif., Sept. 5, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from the pivotal NAVIGATOR Phase 3 trial demonstrating that tezepelumab reduced exacerbations and improved lung function... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - September 5, 2021 Category: Pharmaceuticals Source Type: clinical trials

Famotidine Celebrex combination Does Not Reduce Time to Recovery or Mortality in Critically Ill Patients in the I-SPY COVID Trial
SAN FRANCISCO, Sept. 3, 2021.  Quantum Leap Healthcare Collaborative, the sponsor of the I-SPY COVID Trial, today announced that the Famotidine Celecoxib arm has been dropped from the trial due to futility, based on the low likelihood of... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - September 3, 2021 Category: Pharmaceuticals Source Type: clinical trials

COVID-19 Vaccine Clinical Trial in People With Autoimmune Disease Starts at Feinstein Institutes
MANHASSET, N.Y., Sept. 2, 2021. As part of a new National Institutes of Health (NIH) coronavirus disease 2019 (COVID-19) vaccine clinical trial, The Feinstein Institutes for Medical Research– the science arm of Northwell Health–... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - September 2, 2021 Category: Pharmaceuticals Source Type: clinical trials

Pfizer Announces Start of Phase 3 Clinical Trial in Adults for Its Investigational Vaccine Against Respiratory Syncytial Virus (RSV)
First subjects vaccinated in study of Pfizer’s RSV bivalent prefusion F subunit investigational vaccine candidate in adults ages 60 or older RSV is a common and pervasive cause of severe acute respiratory illness in older adults with no... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - September 2, 2021 Category: Pharmaceuticals Source Type: clinical trials

Astellas Provides Update on ASPIRO Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy
TOKYO, September 1, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., " Astellas " ) announced that it has voluntarily paused screening and dosing of additional participants in its... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - September 1, 2021 Category: Pharmaceuticals Source Type: clinical trials

Data from NIH/NHLBI-Sponsored Phase 2 Trial of Fostamatinib in Hospitalized COVID-19 Patients Published in Clinical Infectious Diseases
SOUTH SAN FRANCISCO, Calif., Sept. 1, 2021. Rigel Pharmaceuticals, Inc. today announced the publication of results from a Phase 2 clinical trial evaluating the safety of fostamatinib for the treatment of hospitalized patients with COVID-19, in... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - September 1, 2021 Category: Pharmaceuticals Source Type: clinical trials

Merck and Ridgeback Biotherapeutics Announce Initiation of Pivotal Phase 3 MOVe-AHEAD Study Evaluating Molnupiravir for Post-Exposure Prophylaxis of COVID-19 Infection
KENILWORTH, N.J.& MIAMI--(BUSINESS WIRE) September 1, 2021-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced today the initiation of the Phase 3 MOVe-AHEAD clinical trial to evaluate... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - September 1, 2021 Category: Pharmaceuticals Source Type: clinical trials

Moderna Announces Submission of Initial Data to U.S. FDA for Its COVID-19 Vaccine Booster
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 1, 2021-- Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced it has initiated its submission to the U.S. Food and... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - September 1, 2021 Category: Pharmaceuticals Source Type: clinical trials

New Affron saffron study shows a quick effect on sleep at low dosage
MADRID, Aug. 31, 2021. Results from a new human clinical study demonstrate a significant capacity for Pharmactive's potent all-natural affron standardized saffron extract to promote restorative sleep. The ingredient showed its effect in a single,... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - September 1, 2021 Category: Pharmaceuticals Source Type: clinical trials

Clinical Trial Provides Preliminary Evidence of a Cure for Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS) and Long Covid
BURLINGAME, CA, September 1, 2021 – Cortene Inc. announces publication of its InTiME clinical trial in which a short subcutaneous infusion of its experimental drug, CT38, achieved sustained symptom improvement in ME/CFS.  The company... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - September 1, 2021 Category: Pharmaceuticals Source Type: clinical trials

SK Bioscience and GSK Start Phase 3 trial of Adjuvanted COVID-19 Vaccine Candidate
Advance to Phase 3 follows positive interim Phase 1/2 immunogenicity and safety data Global clinical trial will evaluate vaccine candidate GBP510 against the AZ/Oxford COVID-19 vaccine Aim is for global supply through the COVAX facility in the... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 31, 2021 Category: Pharmaceuticals Source Type: clinical trials

Teva and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatment for Patients with Schizophrenia
PARSIPPANY, N.J., TEL AVIV& PARIS--(BUSINESS WIRE) August 31, 2021 -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and MedinCell (Euronext: MEDCL)announced today that the New Drug... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 31, 2021 Category: Pharmaceuticals Source Type: clinical trials

Bayer Starts Phase III Clinical Development Program OASIS With Investigational Product, Elinzanetant
Elinzanetant is a non-hormonal development compound investigated for the treatment of vasomotor symptoms during menopause WHIPPANY, N.J.--(BUSINESS WIRE) August 31, 2021-- Bayer, a global leader in women’s healthcare, announced today that... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 31, 2021 Category: Pharmaceuticals Source Type: clinical trials

Novavax Statement on CDC Guidance Update for COVID-19 Clinical Trial Participants
GAITHERSBURG, Md., Aug. 30, 2021. Novavax, Inc. , a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the U.S. Centers for Disease Control and Prevention (CDC) has provided updated... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 30, 2021 Category: Pharmaceuticals Source Type: clinical trials

Positive Top-Line Results From Pfizer ’s Phase 3 JADE DARE Trial Comparing the Efficacy of Abrocitinib and Dupilumab for Moderate to Severe Atopic Dermatitis
NEW YORK--(BUSINESS WIRE) August 30, 2021 -- Pfizer Inc. (NYSE: PFE) today announced that JADE DARE (B7451050), a 26-week, randomized, double-blind, double-dummy, active-controlled, multi-center Phase 3 study, met its co-primary and key secondary... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 30, 2021 Category: Pharmaceuticals Source Type: clinical trials

Study Data Show Abbott's CardioMEMSDevice Can Improve Care for More Patients with Heart Failure
ABBOTT PARK, Ill., Aug. 27, 2021.  Abbott today announced results of the landmark GUIDE-HF clinical trial, a 1,000 patient randomized study designed to assess the benefits of the CardioMEMS HF System in people living with NYHA Class II, III and... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 29, 2021 Category: Pharmaceuticals Source Type: clinical trials

Airway Therapeutics Announces First Patient Dosed in Phase 1b Trial of AT-100 in Severe COVID-19 Patients
CINCINNATI, Aug. 26, 2021.  Airway Therapeutics, Inc. (Airway), a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, announced... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 26, 2021 Category: Pharmaceuticals Source Type: clinical trials

INOVIO Receives Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate
PLYMOUTH MEETING, Pa., Aug. 26, 2021. INOVIO, a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that it... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 26, 2021 Category: Pharmaceuticals Source Type: clinical trials

ALXN1840 FoCus Phase III Trial in Wilson Disease Met Primary Endpoint Demonstrating Improvement in Copper Mobilisation from Tissues
26 August 2021  ALXN1840 demonstrated approximately three times greater copper mobilisation from tissues than standard-of-care treatments  Positive high-level results from the FoCus Phase III trial in Wilson disease showed ALXN1840... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 26, 2021 Category: Pharmaceuticals Source Type: clinical trials

CytoDyn ’s Final mTNBC Report Indicates as Much as 980% Increase in 12-Month Overall Survival and Up to 660% in 12-Month Modified Progression Free Survival
VANCOUVER, Washington, Aug. 25, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ( " CytoDyn " or the " Company " ), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 25, 2021 Category: Pharmaceuticals Source Type: clinical trials

Novavax to Participate in OCTAVE-DUO Study to Evaluate Third Dose of Vaccine in Participants with Impaired Immune Systems
GAITHERSBURG, Md., Aug. 25, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Novavax'recombinant nanoparticle protein... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 25, 2021 Category: Pharmaceuticals Source Type: clinical trials

Oramed Reaches 25% Enrollment in Its Second of Two Concurrent Phase 3 Oral Insulin Trials
NEW YORK, Aug. 24, 2021. Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced today that it has enrolled and randomized over 25% of the planned 450 patients for... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 24, 2021 Category: Pharmaceuticals Source Type: clinical trials

Theravance Biopharma, Inc. Announces Top-line Results from Phase 2b Dose-Finding Induction Study of Izencitinib in Patients with Ulcerative Colitis
Monday, August 23, 2021. Randomized, double-blind, placebo-controlled study did not meet the primary endpoint: change in the total Mayo score at week eight, relative to placebo Izencitinib was well-tolerated and safety data were consistent with... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 24, 2021 Category: Pharmaceuticals Source Type: clinical trials

Theravance Biopharma, Inc. Announces Top-line Results from Phase 2b Dose-Finding Induction Study of Izencitinib in Patients with Ulcerative Colitis
DUBLIN and SOUTH SAN FRANCISCO, Calif., Aug. 23, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. ( " Theravance Biopharma " or the " Company " ) (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 23, 2021 Category: Pharmaceuticals Source Type: clinical trials

AZD7442 PROVENT Phase III Prophylaxis Trial Met Primary Endpoint in Preventing COVID-19
20 August 2021 77% reduced risk of developing symptomatic COVID-19 First long-acting antibody combination to prevent COVID-19 Positive high-level results from the PROVENT Phase III pre-exposure prophylaxis trial showed AstraZeneca's AZD7442... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 20, 2021 Category: Pharmaceuticals Source Type: clinical trials

NRx Pharmaceuticals Announces Positive Safety Report for Zyesami (aviptadil) in NIH Sponsored ACTIV-3 Critical Care Study in Patients with Life-Threatening COVID-19
After Review of Approximately 140 patients in ACTIV-3 Critical Care Study, No New Safety Concerns Raised by Independent Data Safety Monitoring Board, Study to Continue Enrollment to Target More than 600 Patients ACTIV-3 Critical Care is a... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 18, 2021 Category: Pharmaceuticals Source Type: clinical trials

Coherus and Junshi Biosciences Announce Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
Toripalimab plus chemotherapy met primary endpoint with significant improvement in PFS compared to chemotherapy alone Data support the use of toripalimab with chemotherapy as first-line therapy for patients with NSCLC Study to be presented... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 18, 2021 Category: Pharmaceuticals Source Type: clinical trials

Sutro Biopharma Announces STRO-002 FDA Fast Track Designation for Patients with Advanced Ovarian Cancer
SOUTH SAN FRANCISCO, August 18, 2021– Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 18, 2021 Category: Pharmaceuticals Source Type: clinical trials

Statement on Boosting with the Johnson & Johnson COVID-19 Vaccine
NEW BRUNSWICK, N.J., August 18, 2021 -- We are engaging with the U.S. FDA, CDC and other health authorities and will share new data shortly regarding boosting with the Johnson& Johnson COVID-19 vaccine. In July, Johnson& Johnson... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 18, 2021 Category: Pharmaceuticals Source Type: clinical trials

Lilly's Lebrikizumab Significantly Improved Skin Clearance and Itch in People with Moderate-to-Severe Atopic Dermatitis in Two Phase 3 Trials
INDIANAPOLIS, Aug. 16, 2021 /PRNewswire/ -- Lebrikizumab led to significant improvements with at least 75 percent skin clearance in more than half of people with moderate-to-severe atopic dermatitis (AD), as measured by EASI, in Eli... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 16, 2021 Category: Pharmaceuticals Source Type: clinical trials

Moderna Announces First Patient Dosed in Phase 1/2 Study of mRNA-3705 for Methylmalonic Acidemia
mRNA-3705 is Moderna’s second rare disease program to enter clinical studies mRNA-3705 granted Orphan Drug and Rare Pediatric Disease designation by the U.S. FDA MMA associated with significant mortality and morbidity; there are no... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 16, 2021 Category: Pharmaceuticals Source Type: clinical trials

Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study
London UK and Tübingen, Germany / Boston, USA -16 August 2021 Preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone jointly developed by CureVac and GSK compared to CureVac’s... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 16, 2021 Category: Pharmaceuticals Source Type: clinical trials

Pfizer and BioNTech Announce Submission of Initial Data to U.S. FDA to Support Booster Dose of COVID-19 Vaccine
Monday, August 16, 2021 Phase 1 safety and immunogenicity data in individuals who received a third dose of the Pfizer-BioNTech vaccine (BNT162b2) show a favorable safety profile and robust immune responses The booster dose elicited significantly... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 16, 2021 Category: Pharmaceuticals Source Type: clinical trials

Moderna Announces FDA Authorization of Third Dose of COVID-19 Vaccine for Immunocompromised Individuals
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 13, 2021-- Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that the U.S. Food and Drug Administration (FDA) has... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 13, 2021 Category: Pharmaceuticals Source Type: clinical trials

Junshi Biosciences and Coherus Announce U.S. FDA Breakthrough Therapy Designation Granted for Toripalimab for 1st Line Treatment of Nasopharyngeal Carcinoma
1st line nasopharyngeal indication and 2nd/3rd line indications to be concurrently submitted 3Q 2021 in the toripalimab BLA SHANGHAI, China, and REDWOOD CITY, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 12, 2021 Category: Pharmaceuticals Source Type: clinical trials

Moderna Announces New Study Showing Its COVID-19 Vaccine Maintains Antibodies Against Variants of Concern and Interest to 6 Months
Variants studied included Alpha, Beta, Gamma, Delta, Epsilon and Iota Majority of participants who received primary series maintain detectable binding and functional antibodies against variants for 6 months CAMBRIDGE, Mass.--(BUSINESS... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 12, 2021 Category: Pharmaceuticals Source Type: clinical trials

VTX-801 Receives U.S. FDA Fast Track Designation for the Treatment of Wilson Disease
Paris, France and New York, NY, August 12, 2021– Vivet Therapeutics (“Vivet”), a clinical-stage biotechnology company, and Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 12, 2021 Category: Pharmaceuticals Source Type: clinical trials

Australian Therapeutic Goods Administration Grants Provisional Registration for Moderna ’s COVID-19 Vaccine
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 9, 2021-- Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Therapeutic Goods Administration (TGA)... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 9, 2021 Category: Pharmaceuticals Source Type: clinical trials

Exicure Provides Interim Results from Ongoing Phase 1b/2 Clinical Trial of Cavrotolimod (AST-008)
CHICAGO& CAMBRIDGE, Mass.--(BUSINESS WIRE) August 5, 2021 -- Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, is providing an update on the Phase... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 5, 2021 Category: Pharmaceuticals Source Type: clinical trials

Novavax Announces COVID-19 Vaccine Booster Data Demonstrating Four-Fold Increase in Neutralizing Antibody Levels Versus Peak Responses After Primary Vaccination
GAITHERSBURG, Md., Aug. 5, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced preliminary data demonstrating that a single booster... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 5, 2021 Category: Pharmaceuticals Source Type: clinical trials

Pfizer Announces Positive Top-Line Results from Phase 2b/3 Trial of Ritlecitinib in Alopecia Areata
NEW YORK--(BUSINESS WIRE) August 04, 2021-- Pfizer Inc. (NYSE: PFE) today announced positive top-line results from the Phase 2b/3 ALLEGRO trial evaluating oral once-daily ritlecitinib in patients with alopecia areata, an autoimmune disease driven by... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 4, 2021 Category: Pharmaceuticals Source Type: clinical trials

New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV (casirivimab and imdevimab) to Prevent SARS-CoV-2 Infection
TARRYTOWN, N.Y., Aug. 4, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the New England Journal of Medicine (NEJM) published positive detailed results from a... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 4, 2021 Category: Pharmaceuticals Source Type: clinical trials

Complete Response Letter Received from FDA for Treosulfan
TORONTO and CHICAGO and WEDEL, Germany, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the“Company”) (TSX: MDP) (OTCQX: MEDXF) and medac GmbH (“medac”) announced today that medac,... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 3, 2021 Category: Pharmaceuticals Source Type: clinical trials

SpringWorks Therapeutics Announces Phase 1b/2a Clinical Trial of Mirdametinib in Patients with Advanced Solid Cancers Harboring MAPK-Activating Mutations
STAMFORD, Conn., Aug. 03, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 3, 2021 Category: Pharmaceuticals Source Type: clinical trials

Moderna Receives FDA Fast Track Designation for Respiratory Syncytial Virus (RSV) Vaccine (mRNA-1345)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 3, 2021-- Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the U.S. Food and Drug Administration (FDA) has... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 3, 2021 Category: Pharmaceuticals Source Type: clinical trials

Moderna Announces First Participant Dosed in Phase 1 Study of Its IL-2 mRNA Therapeutic
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 2, 2021-- Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the first participant has been dosed in the Phase 1 study of... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 2, 2021 Category: Pharmaceuticals Source Type: clinical trials